Presentation

Basilea is a Swiss commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of anti-infectives. The company was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN. Anti-infectives, specifically antifungals and antibiotics, is the key focus of Basilea’s strategy. The company has successfully brought two anti-infective drugs to the market: the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole). In 2021, the company reported a revenue of CHF 148.1 million, in which CHF 131 million were from the two marketed products Cresemba and Zevtera.

Recent highlights
In February 2022, Basilea announced to focus on anti-infectives and separate its activities in oncology through transactions with partners specialized in oncology. In June 2022, the company announced announced positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB). New Drug Application (NDA) for the US FDA is expected to be submitted by year end 2022.

Outlook
The focus of the company has shifted towards anti-infectives. The aim for the company is to maintain solid revenues of Cresemba and Zevtera as well as expanding their clinical pipeline.